Annals of Oncology Advance Access published online on November 17, 2005
Annals of Oncology, doi:10.1093/annonc/mdj083
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy; Clinical Pharmacology and New Drugs Development Unit, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
* To whom correspondence should be addressed. The characterization of tumor antigens recognized by immune effector cells has opened the perspective of developing therapeutic vaccines in the field of breast cancer. The potential advantages of the vaccines are: (i) the induction of a robust immune response against tumors that are spontaneously weekly immunogenic; (ii) the tumor specificity for some antigens; (iii) the good tolerance and safety profile and (iv) the long-term immune memory, critical to prevent efficiently tumor recurrence. Most trials evaluating breast cancer vaccines have been carried out in patients with extended metastatic breast cancer, characterized by aggressive tumors, resistant to standard cytotoxic treatments, so that clinical efficacy was difficult to achieve. However, some significant immune responses against tumor antigens induced upon vaccinations were recorded. The aim of this review is to analyze the activity of vaccination strategies in current clinical trials. Data of clinical activity have been observed by using vaccines targeting HER2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen and carbohydrate antigen given after stem cell rescue. The review discusses possible future directions for vaccine development and applications in the adjuvant setting.
Received August 29, 2005
Revised October 14, 2005
Accepted October 17, 2005
review
Breast cancer vaccines: a clinical reality or fairy tale?
G. Curigliano 1 *,
G. Spitaleri 1,
E. Pietri 2,
M. Rescigno 3,
F. de Braud 1,
A. Cardillo 2,
E. Munzone 2,
A. Rocca 2,
G. Bonizzi 3,
V. Brichard 4,
L. Orlando 2,
and
A. Goldhirsch 2
2 Department of Medicine, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
3 Division of Experimental Oncology, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
4 Cancer Vaccines Program, GlaxoSmithKline Biologicals, Brussels, Belgium
G. Curigliano, E-mail: giuseppe.curigliano{at}ieo.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors Clin. Cancer Res., February 1, 2009; 15(3): 924 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al. HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405. [Abstract] [Full Text] [PDF]
|
|